Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 5 for:    alyatec

Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04678063
Recruitment Status : Completed
First Posted : December 21, 2020
Last Update Posted : December 21, 2020
Sponsor:
Information provided by (Responsible Party):
Alyatec

Brief Summary:

This is a randomized, double blind, cross-over study designed to determine the concentration of airborne cat allergen inducing bronchial response in asthmatic subjects allergic to cat, during allergen exposures in the Alyatec environmental exposure chamber (EEC).

The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne cat allergen in Alyatec EEC.


Condition or disease Intervention/treatment Phase
Allergic Asthma Allergy Allergy to Cats Other: Exposure to Placebo Other: Exposure to dose A and dose B of cat allergen Other: Exposure to a single dose of cat allergen Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Randomized, double blind, cross-over study including two study groups
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: Validation Study of the ALYATEC Allergen Exposure Chamber (EEC) by Determining the Concentration of Cat Allergen Inducing Early and/or Late Bronchial Response in Asthmatic Subjects Allergic to Cat
Actual Study Start Date : April 10, 2017
Actual Primary Completion Date : June 15, 2017
Actual Study Completion Date : July 11, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Asthmatic subjects allergic to cat
Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
Other: Exposure to Placebo
Patients are exposed to placebo in the EEC

Other: Exposure to dose A and dose B of cat allergen
Patients are exposed to dose A and B for successive exposures in the EEC

Active Comparator: Asthmatic allergic subjects not sensitized to cat
Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
Other: Exposure to Placebo
Patients are exposed to placebo in the EEC

Other: Exposure to a single dose of cat allergen
Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)




Primary Outcome Measures :
  1. Determine the concentration of cat allergen (in ng/m3 of Der p1) necessary to induce a bronchial response in at least 60% of asthmatic subjects allergic to cat. [ Time Frame: 10 hours: 4 hours of exposure in EEC then 6 hours post-exposure ]

    The bronchial response is evaluated by measuring FEV1 value.

    Early asthmatic response (EAR) occurs when a 20 percent drop in FEV1 is detected during the exposure compared to the pre-exposure FEV1.

    Late bronchial response (LAR) occurs when a 15 percent drop in FEV1 or 20 percent drop in peak flow is detected 1 to 6h after the EAR.



Secondary Outcome Measures :
  1. Evaluate the safety of allergenic exposure in EEC [ Time Frame: 28 hours: 4 hours of exposure in EEC then 24 hours post-exposure ]

    Safety is assessed with an asthma symptom self-report questionnaire performed during the 4h exposure and for 24h after the end of the exposure.

    The score was obtained from the sum of all four individual symptom scores (chest tightness, cough, wheezing and dyspnea) with a total possible score ranging from 0 (no symptoms) to 16 (maximum symptom intensity).


  2. Evaluate the allergen concentration in the EEC [ Time Frame: 4 hours exposure in EEC ]
    The measurement of allergen concentration is performed with several sensors positioned in the chamber.

  3. Evaluate the specificity of the bronchial response [ Time Frame: 4 hours exposure in EEC ]
    The specificity of the bronchial response is assessed with the exposure to cat allergen in the EEC of asthmatic allergic subjects non sensitized to cat.

  4. Evaluate the effect of the exposure on rhinitis symptoms [ Time Frame: 28 hours: 4 hours of exposure in EEC then 24 hours post-exposure ]

    The effect of the exposure on the rhinitis response is assessed with Total Nasal Symptom Score (TNSS).

    The TNSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).


  5. Evaluate the effect of the exposure on conjunctivitis symptoms [ Time Frame: 28 hours: 4 hours of exposure in EEC then 24 hours post-exposure ]

    The effect of the exposure on the conjunctivitis response is assessed with Total Ocular Symptom Score (TOSS).

    The TOSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects having signed the informed consent
  • Subjects affiliated to a social security scheme
  • Non-specific bronchial hyperreactivity (HRBNS) assessed by a positive methacholine test
  • FEV1 value > 70% of theoretical FEV1 value
  • Asthma Control Test (ACT) ≥ 20/25 in 4 weeks prior to EEC exposure
  • Women of childbearing potential should have a negative pregnancy test throughout the study period with effective contraception.

Group A:

  • Cat allergic asthma (GINA 1, 2) associated with rhinitis and / or conjunctivitis symptoms triggered during an exposure to a cat.
  • Positive skin prick-test to cat allergen extract (wheal diameter >3 mm compared to the negative control) Specific immunoglobulin E (IgE) for cat allergen > 0.7 kU/L

Group B:

  • Mild allergic asthma (GINA 1 or 2) not sensitized to cat allergen with associated rhinitis and/or conjunctivitis.
  • Negative skin prick-test and specific IgE for cat allergen
  • Positive skin prick-test and specific IgE for another allergen.

Exclusion Criteria:

  • Uncontrolled asthma, ACT asthma control questionnaire less than 20, in the last 4 weeks
  • Uncontrolled asthma 2 weeks after interruption of LABA
  • Long-term treatment by LABA, within 2 weeks prior to inclusion
  • Existence of a severe obstructive syndrome with FEV1 <70% of the theoretical value
  • Obstruction triggered by spirometric evaluations
  • Hospitalization for asthma or exacerbation in the last 4 weeks
  • Subjects treated with oral corticosteroids in the 4 weeks prior to inclusion in the study
  • History of severe acute asthma requiring hospitalization in intensive care or intubation
  • Subjects treated with biotherapy in the 4 months prior to inclusion in the study
  • Presence of a cat at home, or daily exposure to cat allergens
  • Desensitization to cat allergens in the last 6 months
  • Active tobacco: plus 10 cigarettes / day or tobacco history plus 10 PA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04678063


Locations
Layout table for location information
France
Alyatec
Strasbourg, Grand Est, France, 67000
Sponsors and Collaborators
Alyatec
Investigators
Layout table for investigator information
Principal Investigator: Frédéric de Blay, Pr. Alyatec
Additional Information:
Layout table for additonal information
Responsible Party: Alyatec
ClinicalTrials.gov Identifier: NCT04678063    
Other Study ID Numbers: ALY-003
First Posted: December 21, 2020    Key Record Dates
Last Update Posted: December 21, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alyatec:
Cat allergy
Allergic rhinitis
Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Hypersensitivity
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases